transfusions alone for the disease has been projected at ~3,200 USD (equivalent to approximately 1,76,000 Indian rupees) per child, while the lifetime health-care for a person born with the disease has been projected at 284,154 USD (1, 56, 28 ,000 Indian rupees). [8] Though, β-thalassemia is observed in most global populations, each population or sub population has its own unique spectrum of mutations. [9] In India, the estimated number of β-thalassemia heterozygous patients is about 29.7 million with a rate of about 7000 homozygous children born with this disease per year. [10] The frequency of the heterozygous carriers reaches as high as 40% in some tribal groups, whereas, the incidence of the disease is around 3-4% in the general population. [11, 12] About 92% of β-thalassemia allele in India is accounted by common mutations such as IVS 1-5 (c. 92 + 5 G > C), IVS 1-1 (c. 92 + 1 G > T), 619 bp deletion, codon 8/9 (c. 27_28insG), and codon 41/42 (c.124_127delTTCT). [13] The most common mutation across India is IVS 1-5 (c. 92 + 5 G > C) as also found in Pakistan and Sri Lanka. These mutations are not uniformly distributed across India but have geographic specificity, and each ethnic group has some common mutations and a variable number of rare ones. Regional differences in prevalence across northern, eastern and southern parts of India have also been demonstrated.
In the northern states of India, the mutation and allele frequencies are quite similar to those in Pakistan where the two most common mutations are IVS 1-5 (43.5%) and codon 8/9 (38.5%). While in South India [14] codon 41/42 (c. 124_127delTTCT) is prevalent, in Eastern India mutation HBE (codon 26 G-A) (c. 79G > A) is frequently found. [15] The β-globin chain is encoded by the hemoglobin β (HBB) gene. The β-globin locus harbors, in addition to the HBB gene, the ε-globin (HBE) gene, the two γ-globin (HBG) genes (HBG-G and HBG-A) and the δ-globin (HBD) gene. The most genes at this locus are expressed at specific time points in development. During embryonic development, the HBE gene is expressed along with the α-globin gene to form embryonic hemoglobin or HBE. 12 weeks post-conception, the fetus primarily uses fetal hemoglobin (Hb-F), which is composed of two HBG and two α-globin chains. Around the time of birth, HBG production decreases while β-globin synthesis increases so that most individuals have only trace amounts of Hb-F detectable 7-8 months after birth. The combination of two α-globin chains and two β-globin chains makes a normal adult Hb, which becomes the predominant form within 18-24 weeks after birth. Less than 3% of adult hemoglobin is Hb type A2, which is composed of two HBD chains and two α-globin chains. [16, 17] Therefore, any test other that nucleic acid based investigation cannot be used for prenatal diagnosis.
β-thalassemias are heterogenous at the molecular level. [18] Majority of mutations are single nucleotide substitutions, deletions or insertions of olegonucleotides leading to frameshift; rarely it results from gross gene deletion. Point mutations affecting the β-globin expression belong to three different categories: Mutations leading to defective β-gene transcription (promotor and 5' UTR mutations); mutations affecting messenger RNA (mRNA) processing (splice-junction and consensus sequence mutations, polyadenylation, and other 3' UTR mutations); and mutations resulting in abnormal mRNA translation (nonsense, frameshift, and initiation codon mutations). β°-thalassemias are characterized by the complete absence of β-chain production, which results from deletion, initiation codon, nonsense, frameshift, and splicing mutations, especially, at the splice-site junction.
On the other hand, β + -thalassemias are characterized by reduced production of the β-chains, which are produced by mutations in the promoter area, the polyadenylation signal, and the 5'or 3' UTR or by splicing abnormalities.
The population of U.P. is over 200 million; it is a multi-ethnic population but marriages most often take place within the same ethnic groups. As β-thalassemia is inherited in an autosomal recessive manner, couples who are both heterozygous for β-thalassemia gene carry a 25% risk of having a child with β-thalassemia major (homozygous for β-thalassemia gene). Information provided on the distribution and the frequency of β-thalassemia alleles is useful to establish a program for carrier screening, genetic counseling, prenatal diagnosis, and for physicians to establish specific therapeutic approaches for patients suffering from the disease. Due to lack of information regarding the type of β-thalassemia mutations encountered in Western U.P., an effort was made to characterize the mutations for β-thalassemia by ARMS-hot start PCR. 
Materials And Methods

Specimens
Results
The DNA extracted [ Figure 1 ] from the whole blood samples of transfusion dependent β-thalassemia patients were subjected to ARMS-hot start PCR for detection of mutations. This technique is one of the most commonly used techniques for the diagnosis of the disease. The ARMS-hot start PCR results revealed the presence of 4 mutations [ Table 2 ]. Internal control band of 861 bp was present in all ARMS-PCR reactions. Presence of an amplified product by the mutant ARMS primer on 2% agarose gel indicated the presence of the mutant allele.
In the present study, we were able to identify the different β-thalassemia mutations in 28 patients (58%), while mutations were uncharacterized in 20 patients (42%).
The reason for the uncharacterized mutations in these patients could be the presence of mutation other than the five selected mutations or that these patients harbored other hemaglobinopathies. Molecular analysis showed that IVS1-5(G-C) was the commonest β-thalassemic mutation (46%) followed by Fr8/9 (+G), which had a frequency of 21%. The frequency of other mutations was IVS1-1 (12%) and Cd 41/42 (4%). We were not able to find mutation for Cd26 (HBE), which is the 2 nd most widespread mutation in the north eastern states of India [ Table 2 ].
Discussion
Of the 48 patients, we were able to detect four different type of mutations viz. IVS 1-5, CD 41/42, Fr 8/9 and IVS 1-1 in 28 (58%) patients. The most common mutation found in our study was IVS 1-5 (46%), which is in conformity with the previously reported studies as the most common mutation in the Indian population. [15, 19] Therefore, it can fairly be considered as the most common mutation in India.
Mutation Fr 8/9 was found to be the 2 nd most common mutation in our study with a frequency of 21%. This finding is in contrast with the previously reported data, which showed it as the fourth most common mutation in India. [10] Moreover, this mutation was not among the top three mutations in several other parts of the country, viz. Delhi, [20] Chandigarh, [21] Gujarat, [7] and Western India. [22] However, In Eastern India, this mutation ranked as the third most common, HBE being the 2 nd most common mutation, [15] while in South India, the same mutation has a very low frequency of occurrence. Hence, this mutation can be considered unique to Western U.P. High frequency of IVS 1-5 and Fr 8/9 mutations in our study suggests that these may be the oldest β-thalassemia mutations in Western U.P.
The 3 rd most common mutation in Western UP was IVS 1-1 (12%). This conforms with the data previously reported as the third most common mutation in India. [1] However, this mutation was not detected in Southern and Eastern India. [14, 15] The least common mutation detected in the present study was Cd 41/42 (4%); the same was reported from Delhi [20] but is in contrast with the data reported from Chandigarh. [21] An important finding of the present study is that the distribution of Fr 8/9 mutation is high in comparison
with the other regions of the country. To the best of our knowledge, this mutation as the 2 nd most prevalent mutation has never been reported previously from India. Hence, this mutation can be considered unique to Western U.P as HBE is unique to Eastern India.
β-thalassemia has been reported as probably the most common inherited hemoglobin disorder in the Indian subcontinent. [23] Since, no viable forms of treatment are available, the best course is prevention through prenatal diagnosis. Premarital screening in Indian population is still considered controversial, while the same is practiced successfully in Iran and Turkey. [24, 25] Although, the frequency of various β-thalassemia mutations in major cities in different states of India have already been reported, yet the common mutations in various rural areas of the country still need to be explored.
Moreover, no attempt of molecular characterization of β-thalassemia has been carried out in Western U.P region. As each population or sub population has its own unique spectrum of mutations, in the present study, the prevalence of β-thalassemia mutations was investigated in-patients of this area. Through ARMS technique, we were able to analyze mutations in transfusion dependent β-thalassemia patients.
Conclusion
The people in U.P exhibit a genetic heterogeneity that is unparalleled in other regions of India. As only a few prevalent HBB mutations underlie the majority of patients with β-thalassemia in this area, a relatively cost-effective dedicated carrier screening method could be implemented. Furthermore, prenatal diagnosis and other preventive approaches may be the other important strategies in this regard.
